Vanguard Group
ANRO icon

Vanguard Group’s Alto Neuroscience ANRO Stock Holding History

Vanguard Group’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$24.3M Buy
1,365,847
+260,440
+24% +$3.28M ﹤0.01% 2531
2025
Q3 		$4.44M Buy
1,105,407
+20,702
+2% +$68.6K ﹤0.01% 3314
2025
Q2 		$2.39M Sell
1,084,705
-133,940
-11% -$319K ﹤0.01% 3481
2025
Q1 		$2.63M Sell
1,218,645
-11,022
-0.9% -$39.4K ﹤0.01% 3395
2024
Q4 		$5.2M Sell
1,229,667
-43,848
-3% -$274K ﹤0.01% 3253
2024
Q3 		$14.6M Buy
1,273,515
+686,997
+117% +$8.41M ﹤0.01% 2762
2024
Q2 		$6.27M Buy
586,518
+50,186
+9% +$653K ﹤0.01% 3155
2024
Q1 		$8.23M Buy
+536,332
New +$8.39M ﹤0.01% 3068

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group's ANRO Position: Q4 2025 in Review

Vanguard Group increased its Alto Neuroscience (ANRO) stake by 24% in Q4 2025, buying an estimated $3.28M and bringing the position to 1,365,847 shares worth $24.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2531.

Vanguard Group first reported a position in ANRO in Q1 2024 and has held it in 8 quarters since. 97 funds tracked by Wall St. Rank hold ANRO as of Q4 2025.

  • Vanguard Group held 1,365,847 shares of Alto Neuroscience worth $24.3M as of Q4 2025.
  • Vanguard Group bought 260,440 Alto Neuroscience shares in Q4 2025, an estimated $3.28M.
  • Alto Neuroscience made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2531 holding.
  • Vanguard Group first reported a position in Alto Neuroscience in Q1 2024 and has held it in 8 quarters since.
  • 97 funds tracked by Wall St. Rank held Alto Neuroscience as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.